Are you Dr. Pipas?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 46 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1 Medical Center Dr
Department of Hematologyoncology
Lebanon, NH 03756Phone+1 603-650-9474
Summary
- Dr. J. Pipas, MD is an oncologist in Lebanon, New Hampshire. He is currently licensed to practice medicine in New Hampshire.
Education & Training
Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1992 - 1994
Medical University of South CarolinaResidency, Internal Medicine, 1989 - 1992
SUNY Upstate Medical UniversityClass of 1989
Certifications & Licensure
NH State Medical License 1994 - 2022
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Start of enrollment: 2009 Sep 01
- A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer Start of enrollment: 2008 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsCorrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemci...M Kundranda, A C Gracian, S F Zafar, E Meiri, J Bendell
Annals of Oncology. 2020-08-01 - 39 citationsRandomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-...M. Kundranda, A.C. Gracian, S.F. Zafar, E. Meiri, Johanna C. Bendell
Annals of Oncology. 2020-01-01 - 31 citationsRandomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung CancerLecia V. Sequist, Jhanelle E. Gray, Wael A. Harb, Ariel Lopez-Chavez, Robert C. Doebele
The Oncologist. 2019-08-01
Press Mentions
GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee ReviewJuly 31st, 2024- Update: GeoVax Announces Phase 2 Plans for Gedeptin Cancer Therapy Following Clinical Advisory Committee ReviewJuly 31st, 2024
